| Literature DB >> 33559626 |
Massimo Balsano1, Mauro Spina2, Sara Segalla3, Da Broi Michele4, Carlo Doria5.
Abstract
Background The surgical treatment of degenerative disc disease L5-S1 is considerably controversial. The purpose of this study was to evaluate the radiographic and clinical results of patients treated with AxiaLif® Technique (AxiaLif®, AMSGroup, Italy) using a minimally invasive pre-sacral approach. Methods From 2013 to 2018 a total of 52 patients have been treated (12 M, 40 F; mean age 46.3 years). Diagnosis included L5 isthmic spondylolisthesis low-grade dysplasia, primary and secondary degenerative disc disease. 43 patients have been followed for at least 2 years. Fusion assessment was based on plain radiographs and Brantigan fusion criteria at 1, 6, 12 and 24 months after surgery. All patients completed the VAS and ODI at baseline through last follow-up. Results Clinical results showed good pain resolution. VAS back demonstrated an average reduction over baseline of 50%, 57%, 71%, 77% at 3, 6, 12 and 24 months, respectively (p<0.001). ODI demonstrated an average reduction over baseline of 38%, 51%, 67%, and 72% at the same time points (p<0.001). Complete fusion was demonstrated in 65% of cases, 30% partial fusion and 5% in the absence of bony bridges visible radiographically. We had two major complications, as 1 retroperitoneal hematoma and 1 spondylodiscitis, and one minor complication, as a superficial infection of the surgical wound. Conclusions The surgical treatment of degenerative disc disease at L5-S1 with minimally invasive technique Axialif showed good radiographic and clinical outcomes with an acceptable rate of complications. Moreover, shorter hospitalization and faster functional recovery are adding factors to choice this technique.Entities:
Mesh:
Year: 2020 PMID: 33559626 PMCID: PMC7944701 DOI: 10.23750/abm.v91i14-S.11103
Source DB: PubMed Journal: Acta Biomed ISSN: 0392-4203
VAS Back Mean and SD for 43 pts w/ 2-yr follow-up
| Time | Mean | Std. Deviation | N |
| Pre | 7.837 | 1.2522 | 43 |
| 3mo | 3.953 | 1.9634 | 43 |
| 6mo | 3.349 | 1.7027 | 43 |
| 9mo | 2.744 | 1.5133 | 43 |
| 12mo | 2.302 | 1.3008 | 43 |
| 24mo | 1.767 | 1.3063 | 43 |
VAS Back Mean, SE, and 95% CI for 43 pts w/ 2-yr follow-up
| Time | Mean | Std. Error | 95% Confidence Interval | |
| Lower Bound | Upper Bound | |||
| Pre | 7.837 | .191 | 7.452 | 8.223 |
| 3mo | 3.953 | .299 | 3.349 | 4.558 |
| 6mo | 3.349 | .260 | 2.825 | 3.873 |
| 9mo | 2.744 | .231 | 2.278 | 3.210 |
| 12mo | 2.302 | .198 | 1.902 | 2.703 |
| 24mo | 1.767 | .199 | 1.365 | 2.169 |
Note: All VAS Back improvements compared to baseline are highly significant (p<0.001)
Percent Improvements ODI, VAS Back, VAS Leg
| Time | % Improvement | ||
| ODI | VAS Back | VAS Leg | |
| 3mo | 38% | 50% | 42% |
| 6mo | 51% | 57% | 58% |
| 9mo | 60% | 65% | 57% |
| 12mo | 67% | 71% | 69% |
| 24mo | 72% | 77% | 75% |
VAS Leg Mean and SD for 43 pts w/ 2-yr follow-up
| Time | Mean | Std. Deviation | N |
| Pre | 3.674 | 2.5702 | 43 |
| 3mo | 2.140 | 1.8203 | 43 |
| 6mo | 1.535 | 1.4695 | 43 |
| 9mo | 1.581 | 1.4513 | 43 |
| 12mo | 1.140 | .9900 | 43 |
| 24mo | .907 | .9465 | 43 |
VAS Leg Mean, SE, and 95% CI for 43 pts w/ 2-yr follow-up
| Time | Mean | Std. Error | 95% Confidence Interval | |
| Lower Bound | Upper Bound | |||
| Pre | 3.674 | .392 | 2.883 | 4.465 |
| 3mo | 2.140 | .278 | 1.579 | 2.700 |
| 6mo | 1.535 | .224 | 1.083 | 1.987 |
| 9mo | 1.581 | .221 | 1.135 | 2.028 |
| 12mo | 1.140 | .151 | .835 | 1.444 |
| 24mo | .907 | .144 | .616 | 1.198 |
Note: All VAS Leg improvements compared to baseline are highly significant (p<0.001)
ODI Mean and SD for 43 pts w/ 2-yr follow-up
| Time | Mean | Std. Deviation | N |
| Pre | .5019 | .13980 | 43 |
| 3mo | .3116 | .12726 | 43 |
| 6mo | .2465 | .10652 | 43 |
| 9mo | .1984 | .09621 | 43 |
| 12mo | .1679 | .08294 | 43 |
| 24mo | .1381 | .09760 | 43 |
ODI Mean, SE, and 95% CI for 43 pts w/ 2-yr follow-up
| Time | Mean | Std. Error | 95% Confidence Interval | |
| Lower Bound | Upper Bound | |||
| Pre | .502 | .021 | .459 | .545 |
| 3mo | .312 | .019 | .272 | .351 |
| 6mo | .247 | .016 | .214 | .279 |
| 9mo | .198 | .015 | .169 | .228 |
| 12mo | .168 | .013 | .142 | .193 |
| 24mo | .138 | .015 | .108 | .168 |
Note: All ODI improvements compared to baseline are highly significant (p<0.001)
Figure 1.AP (a) and Lat (b) radiological views of lumbar spine shows degenerative disc disease L5-S1.
Figure 2.MRI sagittal image of lumbar spine shows degenerative disc disease L5-S1.
Figure 3.CT sagittal image of lumbar spine shows degenerative disc disease L5-S1.
Figure 4.Two years after implant of AxiaLif device AP (a) and Lat (b) radiological views shows L5-S1 interbody solid fusion.